Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from HeraMED Ltd. ( (AU:HMD) ) is now available.
HeraMED Limited has issued 2,633,860 new fully paid ordinary shares on 12 March 2026, using provisions that allow issuance without a full disclosure document under the Corporations Act. The company states it is fully compliant with financial reporting and continuous disclosure obligations and confirms there is no excluded information that investors are not aware of, signalling a routine capital management step rather than a transformative corporate event.
The cleansing notice assures the market that the newly issued shares can be traded without further disclosure, supporting liquidity for investors and aligning with regulatory requirements. While the announcement does not detail the specific purpose of the capital raised, it maintains HeraMED’s standing as a compliant listed entity and provides transparency around changes to its share capital base.
The most recent analyst rating on (AU:HMD) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on HeraMED Ltd. stock, see the AU:HMD Stock Forecast page.
More about HeraMED Ltd.
HeraMED Limited is an innovative medical data and technology company focused on digitally transforming maternity care through a hybrid prenatal and postpartum platform. Its proprietary ecosystem combines the in‑home, clinically validated HeraBEAT fetal and maternal heart rate monitor with the HeraCARE cloud and AI‑driven software suite to enhance engagement, risk detection and care quality for expectant mothers and healthcare providers.
YTD Price Performance: 11.11%
Average Trading Volume: 654,880
Technical Sentiment Signal: Buy
Current Market Cap: A$44.55M
See more insights into HMD stock on TipRanks’ Stock Analysis page.